natgillin/translations-raw huggingface dataset:
Studies selected had to have at least one acid reflux symptom recording point at 2 weeks.
Izbrane študije so morale vključevati vsaj eno preverjanje simptomov refluksa kisline v 2 tednih.
Concomitant intake of food had no influence on bioavailability (AUC or Cmax), but increased the variability of the lag-time (tlag).
Sočasen vnos hrane ne vpliva na biološko uporabnost (AUC ali Cmax), poveča pa se variabilnost časovnega zamika (tlag).
The following additional risks are considered relevant for long-term use:
Pri dolgotrajni uporabi je treba upoštevati naslednja dodatna tveganja:
HIV-infection) at the same time as pantoprazole, ask your doctor for specific advice.
sočasno s pantoprazolom, prosite zdravnika za poseben nasvet.
If possible take your medicine and this leaflet with you.
Če je mogoče, vzemite s seboj zdravilo in to navodilo.
You should swallow the tablet whole with some water.
Tableto morate pogoltniti celo skupaj z nekaj vode.
Pharmacokinetics do not vary after single or repeated administration.
Farmakokinetika po enkratnem ali večkratnem vnosu se ne razlikuje.
Acid-reflux symptom relief rates were largely independent of the initial GORD stage.
Zmanjšanje simptomov refluksa kisline je bilo večinoma neodvisno od začetne stopnje GERB.
Do not use this medicine after the expiry date, which is stated on the carton and the blister after ‘EXP'.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake “EXP”.
Do not chew or break the tablet.
Ne žvečite ali lomite tablete.
The increased mortality has only been reported in pre-weaning rat pups (up to 21 days age) which is estimated to correspond to infants up to the age of 2 years old.
O povečani umrljivosti so poročali le pri dojenih podganjih mladičih (do 21 dni starosti), kar glede na oceno pri ljudeh ustreza otrokom do dveh let.
Although the main metabolite has a longer half-life (2-3h), excretion is still rapid and thus accumulation does not occur.
Čeprav ima glavni presnovek daljši razpolovni čas (od 2 do 3 ure), je izločanje še vedno hitro in zato kopičenja ni.
Hence it reduces the amount of acid in your stomach.
S tem zmanjša količino kisline v želodcu.
By the end of the recovery phase, bone parameters were similar across groups and body weights were also trending toward reversibility after a drug-free recovery period.
Do konca faze okrevanja so bili parametri kosti podobni v vseh skupinah, trend prirastka telesne mase pa je po obdobju brez zdravila nakazoval na reverzibilnost.
If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.
Če se ravni CgA in gastrina po začetnem merjenju ne vrneta v referenčno območje, je treba meritve ponoviti 14 dni po prekinitvi zdravljenja z zaviralcem protonske črpalke.
Biotransformation Pantoprazole is almost exclusively metabolized in the liver.
Biotransformacija Pantoprazol se skoraj izključno presnavlja v jetrih.
The half-life of the main metabolite (about 1.5 h) is not much longer than that of pantoprazole.
Razpolovni čas glavnega presnovka (približno 1,5 ure) ni veliko daljši od razpolovnega časa pantoprazola.
- ketoconazole (used for fungal infections).
- ketokonazol (uporabljamo ga za zdravljenje glivičnih okužb).
In a retrospective analysis of 17 studies in 5960 patients with gastro-oesophageal reflux disease (GORD) who were treated with 20 mg pantoprazole monotherapy, the symptoms associated with acid reflux e.g. heartburn and acid regurgitation were evaluated according to a standardised methodology.
V retrospektivni analizi 17 študij pri 5.960 bolnikih z gastroezofagealno refluksno boleznijo (GERB), ki so se zdravili z 20 mg pantoprazola v monoterapiji, so simptome refluksa kisline, npr. zgago in regurgitacijo kisline, ovrednotili v skladu s standardno metodologijo.
To avoid this interference, PANTOLOC Control treatment should be stopped for at least 5 days before CgA measurements (see section 5.1).
Da bi to preprečili, je treba vsaj pet dni pred meritvami CgA prekiniti zdravljenje z zdravilom PANTOLOC Control (glejte poglavje 5.1).
This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.
To je treba upoštevati pri bolnikih z zmanjšanimi zalogami vitamina v telesu ali dejavniki tveganja za zmanjšano absorpcijo vitamina B12 pri dolgotrajnem zdravljenju ali ob upoštevanju ustreznih kliničnih simptomov.
Within the following table, adverse reactions are ranked under the MedDRA frequency classification: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Pri uporabi pantoprazola so poročali o naslednjih neželenih učinkih, ki so v tabeli v nadaljevanju navedeni v skladu z navedbo pogostnosti po MedDRA: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Approximately 5% of patients can be expected to experience adverse reactions.
Neželeni učinki se lahko pojavijo pri 5 % bolnikov.
Pantoprazole is metabolized in the liver via the cytochrome P450 enzyme system.
Pantoprazol se presnavlja v jetrih preko encimskega sistema citokroma P450.
As the therapeutic dose in man is low, no side effects on the thyroid glands are expected.
Ker so terapevtski odmerki pri človeku nizki, ni pričakovati neželenih učinkov na ščitnico.
You must not use PANTOLOC Control if you are taking HIV protease inhibitors.
Zdravila PANTOLOC Control ne smete uporabljati, če jemljete zaviralce proteaze HIV.
The effect is the same whether the active substance is given orally or intravenously.
Učinek je enak ne glede na to, ali se zdravilo uporablja peroralno ali intravensko.
After administration of pantoprazole to patients with liver impairment (Child-Pugh classes A, B and C) the half-life values increased to between 3 and 7 h and the AUC values increased by a factor of 3-6, whereas the Cmax only increased slightly by a factor of 1.3 compared with healthy subjects.
Pri uporabi pantoprazola pri bolnikih z okvaro jeter (razredi A, B in C po Child-Pugh-u) se, v primerjavi z zdravimi osebami, razpolovni čas podaljša na 3 do 7 ur, vrednosti AUC zvišajo za 3- do 6-krat, vrednost Cmax pa se komaj opazno zviša, in sicer za faktor 1,3.
Especially, patients over 55 years taking any non-prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor.
Bolniki, predvsem starejši od 55 let, ki zaradi dispeptičnih težav ali zgage vsakodnevno jemljejo katero koli zdravilo brez recepta, morajo o tem obvestiti svojega farmacevta ali zdravnika.
Renal elimination represents the major route of excretion (about 80%) for the metabolites of pantoprazole; the rest is excreted with the faeces.
Glavna pot izločanja presnovkov pantoprazola so ledvice (približno 80 %), preostanek se izloči z blatom.
What PANTOLOC Control is and what it is used for
Kaj je zdravilo PANTOLOC Control in za kaj ga uporabljamo
Other side effects include: - Common (may affect up to 1 in 10 people): Benign polyps in the stomach
Drugi možni neželeni učinki so: - Pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov): benigni polipi v želodcu
Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1.
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Treatment with acid-reducing medicinal products leads to a slightly increased risk of gastrointestinal infections such as Salmonella, Campylobacter, or Clostridium difficile.
Pri zdravljenju z zdravili za znižanje kislosti se nekoliko poveča tveganje za okužbe prebavil, npr. z bakterijami, kot so Salmonella, Campylobacter ali Clostridium difficile.
Investigations revealed no evidence of impaired fertility or teratogenic effects.
Raziskave niso odkrile zmanjšane plodnosti ali teratogenih učinkov.
A previous peri-postnatal study in rats at slightly lower doses found no adverse effects at 3 mg/kg compared with a low dose of 5 mg/kg in this study.
Pri predhodni peri-postnatalni študiji pri podganah pri nekoliko nižjih odmerkih, 3 mg/kg v primerjavi z nizkim odmerkom 5 mg/kg v tej študiji, ni bilo pojava neželenih učinkov.
What PANTOLOC Control is and what it is used for What you need to know before you take PANTOLOC Control How to take PANTOLOC Control Possible side effects
Kaj je zdravilo PANTOLOC Control in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo PANTOLOC Control Kako jemati zdravilo PANTOLOC Control Možni neželeni učinki
Pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity.
Pantoprazol zmanjša kislost v želodcu in posledično zviša gastrin, sorazmerno z znižanjem kislosti.
Tablets should be swallowed whole.
Tablete morate pogoltniti cele.
Your doctor may decide that you need some tests.
Zdravnik se bo morda odločil za dodatne preiskave.
In the 2-year carcinogenicity studies in rats, neuroendocrine neoplasms were found.
Pri podganah so v 2-letnih študijah karcinogenosti ugotovili nevroendokrine neoplazme.
Proton pump inhibitors, especially if used in high doses and over long durations (> 1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in older people or in presence of other recognised risk factors.
Zaviralci protonske črpalke, še posebej če se uporabljajo v velikih odmerkih in daljša obdobja (> 1 leto), lahko rahlo povečajo tveganje zloma kolka, zapestja in hrbtenice, predvsem pri starejših ljudeh ali v prisotnosti drugih priznanih dejavnikov tveganja.
If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping PANTOLOC Control.
Če se pojavijo lezije, zlasti na koži, ki je izpostavljena soncu, in sočasna artralgija, mora bolnik takoj poiskati zdravniško pomoč, zdravstveni delavec pa mora razmisliti o prekinitvi zdravljenja z zdravilom PANTOLOC Control.
In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.
V velikem deležu prizadetih bolnikov se je hipomagnezemija izboljšala po nadomestitvi magnezija in prekinitvi zaviralcev protonske črpalke.
Driving and using machines If you experience side effects like dizziness or disturbed vision, you should not drive or use machines.
Vpliv na sposobnost upravljanja vozil in strojev Če se pojavijo neželeni učinki, kot so omotica ali motnje vida, ne smete voziti vozil ali upravljati strojev.
Disorientation (and all aggravations)
dezorientiran ost (in vsa poslabšanja)
If your reflux symptoms (heartburn or acid regurgitation) persist for longer than 2 weeks, consult your doctor who will decide about the need for long-term intake of this medicinal product.
Če vaši simptomi refluksa (zgaga ali refluks kisline) trajajo dlje kot 2 tedna, se posvetujte s svojim zdravnikom, ki bo presodil, ali je treba to zdravilo dolgotrajno jemati.
- Serious allergic reactions (rare: may affect up to 1 in 1,000 people): Hypersensitivity reactions, so-called anaphylactic reactions, anaphylactic shock and angioedema.
- Resne alergijske reakcije (redke; pojavijo se lahko pri največ 1 od 1.000 bolnikov): preobčutljivostne reakcije, imenovane anafilaktične reakcije, anafilaktični šok in angioedem.
Control that reduces stomach acid.
Control, ki zmanjšuje izločanje želodčne kisline.
Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements.
Razpoložljivi objavljeni podatki kažejo, da je treba zdravljenje z zaviralci protonske črpalke prekiniti od 5 do 14 dni pred merjenjem CgA.
Due to the specific binding of pantoprazole to the proton pumps within the parietal cell, the elimination half-life does not correlate with the much longer duration of action (inhibition of acid secretion).
Zaradi specifične vezave pantoprazola na protonsko črpalko znotraj parietalnih celic, razpolovni čas izločanja ni v korelaciji z njegovim veliko daljšim časom trajanja delovanja (zaviranje izločanja kisline).
Disturbances in vision / blurred vision
Očesne bolezni motnje vida / zamegljen vid
Pharmacotherapeutic group: Drugs for acid related disorders, Proton pump inhibitors, ATC code: A02BC02
Farmakoterapevtska skupina: zdravila za kislinsko pogojene bolezni, zaviralci protonske črpalke, oznaka ATC: A02BC02
- warfarin and phenprocoumon (used to thin blood and prevent clots).
varfarin ali fenprokumon (uporabljamo ju za redčenje krvi in preprečevanje nastanka krvnih strdkov).
After 14 and 28 days, complete heartburn relief was experienced in 62.9% to 88.6% and 68.1% to 92.3% of the patients, respectively.
Po 14 dneh se je zgaga popolnoma izboljšala pri 62,9 % do 88,6 % bolnikov, po 28 dneh pa pri 68,1 % do 92,3 % bolnikov.
Pantoprazole/metabolites have been identified in human milk.
Pantoprazol/presnovke so ugotovili v materinem mleku.
There were no interactions with concomitantly administered antacids.
Medsebojnega delovanja pri sočasnem jemanju antacidov niso ugotovili.
This may cause you symptoms such as a painful burning sensation in the chest rising up to the throat (heartburn) and a sour taste in the mouth (acid regurgitation).
To lahko povzroči bolezenske znake, kot je boleč in pekoč občutek v prsih, ki se dviga proti žrelu (zgaga) in okus po kislem v ustih (regurgitacija kisline).
For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.
Pri bolnikih, za katere se pričakuje dolgotrajno zdravljenje ali ki prejemajo zaviralce protonske črpalke sočasno z digoksinom ali zdravili, ki lahko povzročijo hipomagneziemijo (npr. diuretiki), naj bi zdravstveni delavci izvajali merjenje ravni magnezija pred začetkom zdravljenja z zaviralci protonske črpalke in redno med zdravljenjem.
After 7 days the percentage of patients experiencing complete relief from acid regurgitation was between 61.5% and 84.4%, after 14 days between 67.7% and 90.4%, and after 28 days between 75.2% and 94.5%, respectively.
Po 7 dneh je delež bolnikov s popolnim izboljšanjem simptomov regurgitacije kisline znašal od 61,5 % do 84,4 %, po 14 dneh od 67,7 % do 90,4 %, po 28 dneh pa od 75,2 % do 94,5 %.
The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment.
Mehanizem nastanka želodčnih karcinoidov s substituiranimi benzimidazoli so natančno preučili in zaključili, da gre za sekundarno reakcijo na močno zvišano raven gastrina v serumu, ki se pojavi pri podganah med kroničnim zdravljenjem z velikimi odmerki.
In the dose range of 10 to 80 mg, the plasma kinetics of pantoprazole are linear after both oral and intravenous administration.
V razponu odmerkov od 10 do 80 mg je plazemska kinetika pantoprazola po peroralni in intravenski uporabi linearna.
Doses up to 240 mg administered intravenously over 2 minutes were well tolerated.
Odmerke do 240 mg intravensko, aplicirane v 2 miutah, so preiskovanci dobro prenašali.
Since pantoprazole binds to the enzyme distal to the receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin).
Ker se pantoprazol veže na encim distalno od celičnega receptorja, lahko zavira izločanje klorovodikove kisline neodvisno od stimulacije z drugimi učinkovinami (acetilholin, histamin, gastrin).
In these studies, the percentage of patients experiencing complete relief from heartburn after 7 days was between 54.0% and 80.6% in the pantoprazole group.
V teh študijah je delež bolnikov s popolnim izboljšanjem zgage po 7 dneh zdravljenja v skupini s pantoprazolom znašal od 54,0 % do 80,6 %.
The main metabolite in both serum and urine is desmethylpantoprazole, which is conjugated with sulphate.
Glavni presnovek v serumu in v urinu je dezmetilpantoprazol, ki je konjugiran s sulfatom.
Reflux is the backflow of acid from the stomach into the gullet (“foodpipe”), which may become inflamed and painful.
Refluks je zatekanje kisline iz želodca nazaj v požiralnik (del prebavne cevi med žrelom in želodcem), ki se zaradi tega lahko vname in postane boleč.
Alu/Alu blisters with or without cardboard reinforcement containing 7 or 14 gastro-resistant tablets.
Alu/Alu pretisni omoti s kartonsko oporo ali brez nje, ki vsebujejo 7 ali 14 gastrorezistentnih tablet.
What you need to know before you take PANTOLOC Control
Kaj morate vedeti, preden boste vzeli zdravilo PANTOLOC Control
Patients should not take pantoprazole as a preventive medicinal product.
Bolniki pantoprazola ne smejo jemati v preventivne namene.
The slight increase in AUC and Cmax in elderly volunteers compared with younger subjects was not clinically relevant.
Pri starejših prostovoljcih so v primerjavi z mlajšimi osebami opazili rahel porast vrednosti AUC in Cmax, vendar pa zvišanje klinično ni bilo pomembno.
Pantoprazole should not be used during pregnancy.
Pantoprazola ne smete uporabljati med nosečnostjo.
Patients should not take another proton pump inhibitor or H2 antagonist concomitantly.
Bolniki sočasno ne smejo jemati drugega zaviralca protonske črpalke ali antagonista histaminskih receptorjev H2.
Yellow, oval biconvex film-coated tablets imprinted with “P20” in brown ink on one side.
Rumene, ovalne, bikonveksne filmsko obložene tablete z rjavo oznako “P20” na eni strani.
PANTOLOC Control is available in Alu/Alu blisters with or without cardboard reinforcement.
Zdravilo PANTOLOC Control je na voljo v Alu/Alu pretisnih omotih s kartonsko oporo ali brez nje.
Byk-Gulden-Straße 2, 78467 Konstanz Germany
Byk-Gulden-Straße 2, 78467 Konstanz Nemčija
See ‘Other medicines and PANTOLOC Control'.
Glejte “Druga zdravila in zdravilo PANTOLOC Control” v nadaljevanju.
You may experience relief from your acid reflux and heartburn symptoms after just one day of treatment with PANTOLOC Control, but this medicine is not meant to bring immediate relief.
Simptomi kislega refluksa in zgage se lahko ublažijo že po enem dnevu zdravljenja z zdravilom PANTOLOC Control, vendar pa to zdravilo ni namenjeno za dosego takojšnjega olajšanja.
However, you may take PANTOLOC Control with antacids (e.g. magaldrate, alginic acid, sodium bicarbonate, aluminium hydroxide, magnesium carbonate, or combinations thereof), if needed.
Zdravilo PANTOLOC Control lahko po potrebi jemljete skupaj z antacidi (npr. magaldrat, alginska kislina, natrijev hidrogenkarbonat, aluminijev hidroksid, magnezijev karbonat ali kombinacije naštetih).
PANTOLOC Control contains the active substance pantoprazole, which blocks the ‘pump' that produces stomach acid.
Zdravilo PANTOLOC Control vsebuje zdravilno učinkovino pantoprazol, ki zavira “črpalko”, ki proizvaja želodčno kislino.
You should not take it as a preventive measure.
Tega zdravila ne smete jemati v preventivne namene.
- falling magnesium levels in your blood (potential symptoms: fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate).
- znižane ravni magnezija v krvi (možni simptomi: utrujenost, nenadzorovano krčenje mišic, zmedenost, krči, omotica, zvišan srčni utrip).
• They are on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks.
• če se zaradi dispeptičnih težav ali zgage neprekinjeno simptomatsko zdravijo 4 tedne ali dlje.
Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients.
Pri sočasni uporabi visokih odmerkov metotreksata (npr. 300 mg) in zaviralcev protonske črpalke so pri posameznih bolnikih poročali o zvišanju vrednosti metotreksata.
The fasting gastrin values increase under pantoprazole.
Vrednosti gastrina, izmerjene na tešče, se po uporabi pantoprazola zvišajo.
Patients may start to experience symptomatic relief after approximately one day of treatment with pantoprazole, but it might be necessary to take it for 7 days to achieve complete heartburn control.
Simptomi se lahko ublažijo že približno po enem dnevu zdravljenja s pantoprazolom, vendar pa bo za popolno ublažitev simptomov zgage tablete morda treba jemati 7 dni.
Packs containing 7 or 14 gastro-resistant tablets.
Pakiranja vsebujejo 7 ali 14 gastrorezistentnih tablet.
Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours.
Zvišana raven kromogranina A (CgA) lahko ovira preiskave glede nevroendokrinih tumorjev.
What PANTOLOC Control looks like and contents of the pack The gastro-resistant tablets are yellow, oval, biconvex film-coated tablets imprinted with “P20” on one side.
Izgled zdravila PANTOLOC Control in vsebina pakiranja Gastrorezistentne tablete so rumene, ovalne, obojestransko izbočene filmsko obložene tablete z oznako “P20” na eni strani.
Interaction studies with carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, naproxen, nifedipine, phenytoin, piroxicam, theophylline and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions.
Pri specifičnih preskušanjih s karbamazepinom, kofeinom, z diazepamom, diklofenakom, digoksinom, etanolom, glibenklamidom, metoprololom, naproksenom, nifedipinom, s fenitoinom, piroksikamom, teofilinom in peroralnimi kontraceptivi, ki vsebujejo levonorgestrel in etinilestradiol, klinično pomembnih interakcij sicer niso ugotovili, vendar pa medsebojnega delovanja z drugimi zdravili, ki se presnavljajo z istim encimskim sistemom, ni mogoče izključiti.
Bone Fracture
Zlom kosti
Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia can occur but they may begin insidiously and be overlooked.
Pojavijo se lahko resni neželeni učinki hipomagneziemije, kot so utrujenost, tetanija, delirij, krči, omotica in ventrikularna aritmija, ki pa se lahko pojavijo prikrito in se jih spregleda.
In the 2-year rodent studies an increased number of liver tumors was observed in rats (in one rat study only) and in female mice and was interpreted as being due to pantoprazole's high metabolic rate in the liver.
V 2-letnih študijah pri glodavcih so pri podganah (samo v 1 študiji) in pri mišjih samicah opazili povečano število jetrnih tumorjev, kar naj bi bila posledica močno povečanega presnavljanja pantoprazola v jetrih.
- reduced absorption of Vitamin B12, and Vitamin B12 deficiency if you already have low body stores of Vitamin B12 - fracture of your hip, wrist or spine, especially if you already suffer from osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).
Če zdravilo PANTOLOC Control prejemate daljše obdobje, lahko to povzroči dodatna tveganja, kot so: - zmanjšana absorpcija vitamina B12 in pomanjkanje vitamina B12, če že imate nizke telesne zaloge vitamina B12 - zlom kolka, zapestja ali hrbtenice, še posebej, če že trpite zaradi osteoporoze ali če jemljete kortikosteroide (ki lahko povečajo tveganje za osteoporozo).
However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.
V dosedanjih študijah pri ljudeh niso opazili tvorbe karcinoidnih predstopenj (atipična hiperplazija) ali želodčnih karcinoidov, kot so jih ugotovili pri poskusih na živalih (glejte poglavje 5.3).
Clearance is about 0.1 l/h/kg, and terminal half-life (t1/2) about 1 h. There were a few cases of subjects with delayed elimination.
Očistek je približno 0,1 l/h/kg, končni razpolovni čas (t1/2) pa približno 1 ura.